ArticlePloS one2012
An RNA interference lethality screen of the human druggable genome to identify molecular vulnerabilities in epithelial ovarian cancer.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 59 citations in OpenAlex.
- Genetic Changes in Mastocytes and Their Significance in Mast Cell Tumor Prognosis and Treatment.Genes · 2024Review
- Inducing Mitotic Catastrophe as a Therapeutic Approach to Improve Outcomes in Ewing Sarcoma.Cancers · 2023Article
- NUF2 is correlated with a poor prognosis and immune infiltration in clear cell renal cell carcinoma.BMC urology · 2023Article
- NUF2 promotes tumorigenesis by interacting with HNRNPA2B1 via PI3K/AKT/mTOR pathway in ovarian cancer.Journal of ovarian research · 2023Article
- NamiRNA-mediated high expression of KNSTRN correlates with poor prognosis and immune infiltration in hepatocellular carcinoma.Contemporary oncology (Poznan, Poland) · 2023Article
- NUF2 overexpression contributes to epithelial ovarian cancer progressionFrontiers in oncology · 2022Article
- Role of chromosome 1q copy number variation in hepatocellular carcinoma.World journal of hepatology · 2021Review
- Potential Prognostic Immune Biomarkers of Overall Survival in Ovarian Cancer Through Comprehensive Bioinformatics Analysis: A Novel Artificial Intelligence Survival Prediction System.Frontiers in medicine · 2021Article
- Article
- QuaDMutNetEx: a method for detecting cancer driver genes with low mutation frequency.BMC bioinformatics · 2020Article
- Review
- Random-forest algorithm based biomarkers in predicting prognosis in the patients with hepatocellular carcinoma.Cancer cell international · 2020Article
- Pleiotrophin: Activity and mechanism.Advances in clinical chemistry · 2020Review
- Nuclear division cycle 80 complex is associated with malignancy and predicts poor survival of hepatocellular carcinoma.International journal of clinical and experimental pathology · 2019Article
- Generation of a cancer testis antigen mCherry reporter HCT116 colorectal carcinoma cell line.Heliyon · 2018Article
- Identification of Genes and Pathways Involved in Ovarian Epithelial Cancer by Bioinformatics Analysis.Journal of Cancer · 2018Article
- Identification of differentially expressed genes and signaling pathways in ovarian cancer by integrated bioinformatics analysis.OncoTargets and therapy · 2018Article
- Bioinformatics analysis of SRSF1-controlled gene networks in colorectal cancer.Oncology letters · 2017Article
- Targeting mitotic pathways for endocrine-related cancer therapeutics.Endocrine-related cancer · 2017Review
- In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
Abstract
Targeted therapies have been used to combat many tumor types; however, few have effectively improved the overall survival in women with epithelial ovarian cancer, begging for a better understanding of this deadly disease and identification of essential drivers of tumorigenesis that can be targeted effectively. Therefore, we used a loss-of-function screening approach to help identify molecular vulnerabilities that may represent key points of therapeutic intervention. We employed an unbiased high-throughput lethality screen using a 24,088 siRNA library targeting over 6,000 druggable genes and studied their effects on growth and/or survival of epithelial ovarian cancer (EOC) cell lines. The top 300 "hits" affecting the viability of A1847 cells were rescreened across additional EOC cell lines and non-tumorigenic, human immortalized ovarian epithelial cell lines. Fifty-three gene candidates were found to exhibit effects in all tumorigenic cell lines tested. Extensive validation of these hits refined the list to four high quality candidates (HSPA5, NDC80, NUF2, and PTN). Mechanistic studies show that silencing of three genes leads to increased apoptosis, while HSPA5 silencing appears to alter cell growth through G1 cell cycle arrest. Furthermore, two independent gene expression studies show that NDC80, NUF2 and PTN were significantly aberrantly overexpressed in serous adenocarcinomas. Overall, our functional genomics results integrated with the genomics data provide an important unbiased avenue towards the identification of prospective therapeutic targets for drug discovery, which is an urgent and unmet clinical need for ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.